Free Trial
NASDAQ:HUMA

Humacyte (HUMA) Stock Price, News & Analysis

$7.54
-0.20 (-2.58%)
(As of 04:02 PM ET)
Today's Range
$7.43
$7.97
50-Day Range
$4.70
$9.10
52-Week Range
$1.96
$9.97
Volume
2.07 million shs
Average Volume
1.99 million shs
Market Capitalization
$897.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.60

Humacyte MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
13.0% Upside
$8.60 Price Target
Short Interest
Bearish
8.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of Humacyte in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$12.46 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.95) to ($0.73) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.50 out of 5 stars

Medical Sector

701st out of 896 stocks

Biological Products, Except Diagnostic Industry

121st out of 152 stocks

HUMA stock logo

About Humacyte Stock (NASDAQ:HUMA)

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

HUMA Stock Price History

HUMA Stock News Headlines

Humacyte (NASDAQ:HUMA) Shares Gap Up Following Analyst Upgrade
Top Stock Unveiled!
Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.
Humacyte Target of Unusually Large Options Trading (NASDAQ:HUMA)
Humacyte (NASDAQ:HUMA) Given New $11.00 Price Target at BTIG Research
Short Interest in Humacyte, Inc. (NASDAQ:HUMA) Rises By 58.7%
Top Stock Unveiled!
Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.
Benchmark Co. Keeps Their Buy Rating on Humacyte (HUMA)
See More Headlines
Receive HUMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/10/2024
Today
7/19/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:HUMA
Fax
N/A
Employees
183
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.60
High Stock Price Target
$15.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+12.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-110,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.57 million
Book Value
$0.13 per share

Miscellaneous

Free Float
91,576,000
Market Cap
$914.53 million
Optionable
Optionable
Beta
1.51
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Laura E. Niklason M.D. (Age 61)
    Ph.D., Founder, President, CEO & Director
    Comp: $899.25k
  • Mr. Dale A. Sander (Age 64)
    CFO, Chief Corporate Development Officer & Treasurer
    Comp: $704.33k
  • Dr. Heather Ledbetter Prichard Ph.D. (Age 46)
    Chief Operating Officer
    Comp: $647.78k
  • Dr. Juliana L. Blum Ph.D.
    Co-Founder & Executive Advisor
  • Ms. Sabrina Osborne
    Executive Vice President of Business Strategy & People
  • Mr. William John Scheessele (Age 52)
    Chief Commercial Officer
  • Dr. Shamik J. Parikh M.D. (Age 51)
    Chief Medical Officer
    Comp: $514.72k
  • Mr. Harold Alterson
    Senior Vice President of Quality
  • Dr. Yang Cao M.D. (Age 58)
    Ph.D., Chief Regulatory Officer

HUMA Stock Analysis - Frequently Asked Questions

How have HUMA shares performed this year?

Humacyte's stock was trading at $2.84 at the beginning of the year. Since then, HUMA stock has increased by 168.0% and is now trading at $7.61.
View the best growth stocks for 2024 here
.

How were Humacyte's earnings last quarter?

Humacyte, Inc. (NASDAQ:HUMA) posted its quarterly earnings data on Friday, May, 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.06.

Who are Humacyte's major shareholders?

Humacyte's top institutional investors include ARS Investment Partners LLC (0.10%). Insiders that own company stock include Laura E Niklason, Brady W Dougan, Gordon M Binder, Dale A Sander, William John Scheessele, Michael T Constantino and Heather Ledbetter Prichard.
View institutional ownership trends
.

How do I buy shares of Humacyte?

Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HUMA) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners